Patents by Inventor Laman L. Alani

Laman L. Alani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Self-emulsifying formulations of CETP inhibitors
    Patent number: 8486983
    Abstract: A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)>10.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: July 16, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Agam R. Sheth, Bhagwant Rege, Soumojeet Ghosh, Laman L. Alani, Maria T. Cruanes, Craig A. McKelvey
  • Solid pharmaceutical dosage formulation
    Patent number: 8377952
    Abstract: The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: February 19, 2013
    Assignee: Abbott Laboratories
    Inventors: Jöerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jörg Breitenbach, Laman L. Alani, Soumojeet Ghosh
  • Solid Pharmaceutical Dosage Form
    Publication number: 20120202858
    Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
    Type: Application
    Filed: April 18, 2012
    Publication date: August 9, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Jöerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jörg Breitenbach, Laman L. Alani, Soumojeet Ghosh
  • Solid Pharmaceutical Dosage Form
    Publication number: 20120022089
    Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
    Type: Application
    Filed: September 22, 2011
    Publication date: January 26, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Jöerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jörg Breitenbach, Laman L. Alani, Soumojeet Ghosh
  • Solid Pharmaceutical Dosage Form
    Publication number: 20110008430
    Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
    Type: Application
    Filed: September 13, 2010
    Publication date: January 13, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Jorg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jorg Breitenbach, Laman L. Alani, Soumojeet Ghosh
  • Self-Emulsifying Formulations of CETP Inhibitors
    Publication number: 20090186926
    Abstract: A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)>10.
    Type: Application
    Filed: December 5, 2006
    Publication date: July 23, 2009
    Inventors: Agam R. Sheth, Bhagwant Rege, Soumojeet Ghosh, Laman L. Alani, Maria T. Cruanes, Craig A. Mckelvey
  • Angiotensin II Receptor Antagonists
    Publication number: 20090123538
    Abstract: The compounds of the present invention are polymorphic crystalline forms of the compound 2-butyl-4-chloro-1-[(2?-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid, which has the structure (I).
    Type: Application
    Filed: April 14, 2006
    Publication date: May 14, 2009
    Inventors: Laman L. Alani, David C. Dubost, Bruce S. Foster, Soumojeet Ghosh, Hossain Jahansouz, Nazaneen Pourkavoos, Bhagwant Rege, Aditya Tatavarti
  • Solid Pharmaceutical Dosage Formulation
    Publication number: 20080299203
    Abstract: The present invention provides a pharmaceutical dosage formulation, and more particularly, a pharmaceutical dosage formulation comprising an HIV protease inhibitor.
    Type: Application
    Filed: August 12, 2008
    Publication date: December 4, 2008
    Inventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jorg Breitenbach, Laman L. Alani, Soumojeet Ghosh
  • Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
    Publication number: 20080145430
    Abstract: The present invention is directed to a novel pharmaceutical composition suitable for ophthalmic use comprising nanoparticles dispersed in a liquid dispersion medium, wherein said nanoparticles comprise a cyclooxygenase-2 selective inhibitor having adsorbed on the surface thereof at least one surface stabilizer. The ophthalmic formulation of the present invention is stable, non-irritating and sufficiently bioavailable. The invention also encompasses a process for making as well as a kit for preparing the novel ophthalmic formulation.
    Type: Application
    Filed: December 5, 2005
    Publication date: June 19, 2008
    Inventors: Santipharp Panmai, Laman L. Alani